Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Education for prevention, early identification, and action on Fatty Liver
Steatotic Liver Disease, including MASLD and MASH
Here are a Few of Our Recent Blog Posts
January 1, 2026: Message from Michael Betel, President and Founder
The Fatty Liver Alliance (FLA) is a global patient-led organization dedicated to education as the front line of prevention, early identification, and action in liver and metabolic disease.
FLA translates rapidly evolving liver and metabolic science into practical, accessible education for patients, communities, and healthcare professionals. We focus on meeting people where they are, whether that is at international medical conferences, in primary care practices, or directly within communities at risk.
Our work spans the full education continuum. We share timely insights from leading liver and metabolic conferences through FLA Live. We deliver community-based education and awareness through Your Liver, Your Health events. We provide walk-in, non-clinical education using non-invasive tools through the Liver Health Awareness Centre. And we equip frontline clinicians through professional education, including our annual Primary Care Summit.
Across all programs, FLA’s role is consistent: to make complex science understandable, relevant, and actionable, and to help individuals and providers recognize liver risk earlier, before irreversible disease develops.
FLA does not diagnose or treat disease. We educate, contextualize risk, and encourage informed follow-up within the healthcare system. Our work is grounded in lived experience, real-world data, and collaboration with researchers, clinicians, and global liver organizations.
By advancing education across global, local, and individual levels, the Fatty Liver Alliance works to close the gap between knowledge and action in liver and metabolic health.
MASLD/MASH: is primary care Ready to automate?
Professor Jeffrey V. Lazarus framed MASLD and MASH as conditions that primary care is uniquely positioned to address. Central to his message was the need to normalize people-first language, automate early detection, and embed liver health into routine metabolic care.
He emphasized that while imaging will ultimately be required for many patients, meaningful progress can already be made using laboratory-based tools, particularly when testing pathways are automated. MASLD should be viewed as a core manifestation of metabolic dysfunction, closely linked with obesity, type 2 diabetes, and cardiovascular risk, rather than a siloed liver condition.
Understanding MASLD and MASH and the relationship between - Primary Care and the Hepatologist
.jpeg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:388,cg:true)
Why Primary Care Cannot Afford to Miss MASLD and MASH:
At the EU First Annual Primary Care MASLD/MASH Summit, we had the privilege of hearing from Dr. Jörn M. Schattenberg, Professor of Medicine and Director of the Department of Medicine II at Saarland University Medical Center in Homburg, Germany (not Hamburg, as many assume).
Dr. Schattenberg brings a rare combination of clinical insight, translational research leadership, and real-world primary care relevance. His work spans EU-funded collaborations such as Liver Aim and GRIP on MASH, and he is the incoming Chair of the UEG Scientific Committee and Associate Editor of JHEP Reports.
We had 2 MASLD MASH Primary Care Summits: North American and European
We hope you had a chance to join the 4th Annual MASLD/MASH Summit & the 1st European Edition – Two Virtual Events on December 4, 2025
These two editions offered an important opportunity to bring together primary care professionals, hepatologists, researchers, and public health leaders from across regions to advance the understanding and management of MASLD/MASH in clinical practice.
The Year Everything Changed for MASLD and MASH: A New Era of Detection, Treatment, and Hope
A New Era for Fatty Liver Disease
The science of liver health has reached a turning point.
At AASLD’s The Liver Meeting 2025, experts confirmed that Steatotic Liver Disease (MASLD/MASH) is now detectable, treatable, and with early action, reversible.
From breakthrough therapies and non-invasive tests to nutrition, exercise, and global collaboration, this comprehensive Fatty Liver Alliance report highlights the key findings shaping the future of liver care.
👉 Read the full report: “The Year Everything Changed for MASLD and MASH.”
Sarcopenia in the Era of GLP-1 Medications: Sarcopenia in the Era of GLP-1 Medications
Over the past few years, GLP-1 receptor agonists like semaglutide and tirzepatide have changed the landscape of metabolic medicine.
Their ability to produce unprecedented levels of sustained weight loss, up to 15–20 percent in clinical trials, has offered real hope to people living with obesity, type 2 diabetes, and metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).
But as Dr. Damian Wijeyesinghe reminded us in his recent presentation at the Durham Care Obesity Symposium, even the most powerful therapies require thoughtful balance. His session, “Sarcopenia in the Era of GLP-1 Medications,” explored an emerging question: as we lose fat, are we also losing too much muscle?
Not All Risks Are Equal: New USC Study Reveals Which Factors Drive Death in MASLD!
This study moves beyond identifying who has MASLD, because it highlights who is most at risk for serious outcomes, reframing how clinicians should approach early care.
Are Liver Health Supplements a Helpful Boost or Risky Business?
Walk into any pharmacy or scroll through social media, and you’ll likely encounter bold claims about liver cleanses, detox kits, and natural liver boosters.
With rising awareness around fatty liver disease, it's no surprise that supplements targeting liver health have exploded in popularity.
But are they effective? Are they safe? What should clinicians and patients really know?
Halfway There: Data-Driven Proof That Lifestyle Change Works
I’m just about halfway through my 30-Day Glucose Challenge, and the results speak for themselves.
Since June 29, I’ve kept my glucose in range 96% of the time, proving that simple, sustained choices can drive measurable improvements. But it’s not just glucose stability I’m seeing.
Join the 30 Day Glucose Challenge – Starting July 1!
The Fatty Liver Alliance invites you to take part in our 3rd Annual 30 Day Glucose Challenge, starting July 1!
This challenge is a powerful opportunity to raise awareness and take action around Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), two of the most common and underdiagnosed liver conditions linked to insulin resistance and glucose spikes.
By using a Continuous Glucose Monitor (CGM) for 10, 15, 20, or 30 days, you'll learn in real time how food, activity, stress, and sleep affect your glucose levels, and by extension, your liver health.
Compassion First: The Cure for Stigma in MASLD and MASH Care
What if the first step in treating liver disease isn’t a test, a medication, or even a diagnosis, but how we speak?
That was the heart of the opening keynote at the Your Health Matters Summit. where Dr. Sean Wharton and Dr. Gillian Mandich challenged us to rethink how we approach people living with obesity and chronic conditions like MASLD and MASH, and it’s exactly what the People-First Liver Charter, published in Nature Medicine, is all about.
Case in Point: Joy’s Journey Through MASH - How Experts Would Manage This Complex Patient
This expert panel discussion highlighted the multidisciplinary, patient-centered approach needed to manage complex MASH cases like Joy’s, emphasizing practical strategies across lifestyle, pharmacotherapy, mental health, and system-level collaboration to drive meaningful, sustainable outcomes.
Our Team
Our History
Our History
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our History
Our History
Our History
The Fatty Liver Alliance was established to address a growing gap between the rising burden of fatty liver disease and the lack of public understanding, early identification, and practical education.
In Canada, with a population of approximately 38.8 million, an estimated 15.5 million people may be living with Metabolic dysfunction-Associa
The Fatty Liver Alliance was established to address a growing gap between the rising burden of fatty liver disease and the lack of public understanding, early identification, and practical education.
In Canada, with a population of approximately 38.8 million, an estimated 15.5 million people may be living with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD. Of these, an estimated 20–25% may progress to Metabolic dysfunction-Associated Steatohepatitis (MASH), placing them at risk for advanced fibrosis, cirrhosis, and related complications.
Despite this prevalence, many individuals remain undiagnosed until disease is advanced, and both patients and frontline healthcare providers often lack access to clear, practical education about liver risk and next steps.
The Fatty Liver Alliance was created to build a supportive, patient-led community and to advance education as a foundation for prevention, early identification, and informed action. Over time, this focus has expanded from awareness alone to community-based education, professional education, and advocacy for equitable access to appropriate care.
Today, FLA works across communities, healthcare settings, and global forums to help close the gap between what is known about fatty liver disease and what happens in real life.
Our Mission
Our History
Our Mission
To advance education that supports prevention, early identification, and action in fatty liver disease, and to advocate for equitable access to care for people with MASLD or MASH.
I want to get involved!
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
